Former Takeda Employee Pleads Guilty to Defrauding Company
By Sabela Ojea
A former Takeda Pharmaceutical senior employee has pleaded guilty to defrauding the company of least $2.3 million.
Priya Bhambi, who served in the pharmaceutical company's technology-operations team, on Wednesday pleaded guilty to one of count of conspiracy to commit wire fraud and three counts of wire fraud, the District of Massachusetts' U.S. Attorney's Office said.
In a co-led scheme, Bhambi submitted fabricated invoices on behalf of a sham consulting company called Evoluzione Consulting whose website Bhambi allegedly created, the Attorney's Office added.
From March 2022 to May 2022, Takeda paid five separate invoices for services that Evoluzione hadn't performed, each in the amount of $460,000, according to the Attorney's Office.
With the money, Bhambi and the co-conspirator allegedly bought a diamond engagement ring, purchased a Mercedes-Benz Model E, made a down payment on a $1.9 million Boston condominium and put in place a deposit on a wedding venue.
In connection with the charges, the court issued seizure warrants for the Mercedes, over $1 million in fraud proceeds from accounts the defendants controlled, $49,985 from the wedding-venue deposit, and issued a restraining order to preserve the Seaport condominium for forfeiture, the Attorney's Office said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
June 06, 2024 19:28 ET (23:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks